The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- Lagos Mainland reconstructs flood-prone Jebba-Osholake road
- MTN Nigeria opens data, network operations for public scrutiny
- First lady partners with ANSACA to boost HIV awareness in Anambra
- Association calls for inclusive implementation of Nigeria’s NDC
- Parents urged to support teachers, not harass them
- Plastic waste to housing materials to tackle Nigeria’s housing shortage
- N-HYPPADEC distributes power tillers to Kaduna farmers
- World Menstrual Hygiene Day: Sokoto stakeholders renew commitment to girls’ health, dignity
